Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

NCT04387942 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT04387942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04387942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
Lead sponsor
The First Hospital of Jilin University
Phase
Not applicable
Overall status
Completed
Start date
June 14, 2020
Completion date
June 30, 2022
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

purpura, schoenlein-henoch